Trial Profile
Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 01 Jan 2022 Results of post-hoc analysis using pooled data from phase IIb and a phase III studies (NCT00527033 & NCT00966004) assessing efficacy of mirabegron were published in the International Journal of Urology.
- 28 Jan 2014 Results published in the BJU International.
- 18 Jun 2010 Primary endpoint 'Micturition rate' has been met according to an Astellas Pharma media release.